<DOC>
	<DOCNO>NCT00984386</DOCNO>
	<brief_summary>The purpose study investigate early wound heal one application four different dos intradermal Zesteem ( 17β-Estradiol ) male subject female subject two year post-menopausal .</brief_summary>
	<brief_title>Investigation Efficacy Zesteem Accelerating Early Wound Healing</brief_title>
	<detailed_description>Each subject receive total six , 3mm punch biopsy wound ; three wound upper inner aspect arm . Each punch biopsy site randomly allocate receive one six treatment : Zesteem ( 0.02μg , 0.1μg , 0.2μg 0.4μg/100μl ) , Placebo ( vehicle ) , Standard Care ( moist wound heal dressing ) . Zesteem Placebo administer mark , anaesthetise site , intradermal injection 10 30 minute wound . Sites randomise receive Standard Care receive additional treatment wounding . After wound , sit receive moist wound heal dressing ( Standard Care ) . Three day wound , biopsy site anaesthetise wound excise use 5mm punch biopsy , histological analysis . The Investigator close excision site use suture Steri-strips achieve cosmetically acceptable result . Subjects attend post-trial follow-up visit ( 13-18 day dose ) suture remove final safety assessment perform .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Cicatrix</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Male subject age 1885 year , female subject least two year postmenopausal ( quantified serum test result estradiol &lt; 90 pmol/L FSH &gt; 31 IU/L ) give write informed consent Subjects BMI within permitted range height use Quetelet 's indexweight ( kg ) /height² ( ) . The permitted index 1555 kg/m2 Subjects , opinion investigator , clinically acceptable result laboratory safety test perform within 28 day first trial dose administration Subjects direct question physical examination history evidence hypertrophic keloid scar Subjects tattoos previous scar within 3cm area biopsied AfroCaribbean subject exclude increased susceptibility hypertrophic keloid scar Subjects surgery area biopsied within one year first dose day Subjects history bleed disorder Subjects skin disorder chronic currently active Investigator considers adversely affect heal acute wound involve area examine trial Subjects clinically significant medical condition history would impair wound heal include : significant rheumatoid arthritis , chronic renal impairment significant age , significant hepatic impairment ( LFTs &gt; 3 time upper limit normal ) , congestive heart failure , current active malignancy history malignancy last 5 year , immunosuppression chemotherapy within last 12 month , history radiotherapy diabetes mellitus Subjects history hypersensitivity drug dressing use trial Subjects taking , take investigational product participate clinical trial three month prior first trial dose administration Subjects take regular , continuous , oral corticosteroid therapy Subjects undergoing investigation change management exist medical condition Subjects history drug abuse Subjects positive drug abuse test cocaine , amphetamine , methamphetamine , opiates benzodiazepine screen period Subjects , opinion investigator , unlikely complete trial whatever reason Female subject currently take form hormone replacement therapy contraceptive medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cicatrix</keyword>
	<keyword>Scar</keyword>
	<keyword>Wound-healing</keyword>
	<keyword>Zesteem</keyword>
	<keyword>17β-Estradiol</keyword>
	<keyword>RN1002</keyword>
</DOC>